Schall, Brown & Schwartz Files Securities Fraud Suit Against Beta Bionics
Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.
Class period spans July 2025 to February 2026 amid disputed FDA findings
The class covers purchasers of Beta Bionics common stock between July 30, 2025 and February 24, 2026. Investors face a November 3, 2026 deadline to seek appointment as lead plaintiff.